Skip to main content

Treatment Modification Common With Second-Line Antidiabetic Meds

Medically reviewed by Carmen Pope, BPharm. Last updated on Dec 14, 2023.

By Elana Gotkine HealthDay Reporter

THURSDAY, Dec. 14, 2023 -- Most patients with type 2 diabetes initiating antidiabetic medication (ADM) experience treatment modification within one year, according to a study published in the December issue of the American Journal of Managed Care.

David T. Liss, Ph.D., from the Northwestern University Feinberg School of Medicine in Chicago, and colleagues conducted a retrospective cohort study to describe changes in ADM use after initiation of noninsulin second-line therapy. Adults with type 2 diabetes who initiated one of five index ADM classes were analyzed; three treatment modification outcomes were assessed over 12-month follow-up.

The researchers found that 63.6 percent of the 82,624 included adults experienced any treatment modification. The most common modification was discontinuation (38.6 percent), especially among those prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RAs; 50.3 percent). Switching and intensification occurred in 5.2 and 19.8 percent of patients, respectively. In adjusted analyses, discontinuation risk was higher among patients prescribed dipeptidyl peptidase 4 inhibitors and GLP-1 RAs compared with those prescribed sulfonylureas (hazard ratios, 1.07 and 1.28, respectively). Higher risks of switching and lower risks of intensification were seen for all other index ADM classes compared with sulfonylureas. Higher risk of all modifications was seen in association with younger age group and female sex. Index prescription by an endocrinologist was associated with lower discontinuation risk and higher intensification risk compared with index prescription by a family medicine or internal medicine physician.

"Future research is needed to improve our understanding of barriers to ADM adherence among patients who discontinue second-line therapy," the authors write.

One author disclosed ties to the pharmaceutical industry.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Read this next

BMI Cutoff of 30 for Obesity May Be Too High for Middle-Aged, Older Adults

FRIDAY, May 31, 2024 -- The optimal body mass index (BMI) cutoff point appears to be 27 kg/m2 for detecting obesity in middle-aged and older adults, according to a study presented...

Emergency Inguinal Hernia Surgery Rates Increased With Lower Country Income

FRIDAY, May 31, 2024 -- For patients undergoing inguinal hernia surgery, emergency surgery rates increase from high- to low-income countries, according to a study published online...

Maternal Serum Alpha-Fetoprotein Levels Higher in Black Than White Women

FRIDAY, May 31, 2024 -- Maternal serum alpha-fetoprotein (AFP) levels are higher in Black than White pregnant women, supporting the use of accounting for these differences in...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.